AHLUWALIA CONTRACTS: CO WINS ORDER WORTH RUPEES 310 CR

BHEL: Q2 SL NET PROFIT 8.1B RUPEES VS 3.68B (YOY); EST 6.54B

BHEL: Q2 EBITDA 10B RUPEES VS 5.8B (YOY), EST 8.81B; Q2 EBITDA MARGIN 11.03% VS 7.73% (YOY), EST 9.5%

BHEL: Q2 REVENUE 93B RUPEES VS 75.12B (YOY); EST 92.36B

GROWW: Q2 CONS NET PROFIT 7.3B RUPEES VS 4.7B (YOY); EST 6.8B

GROWW: Q2 EBITDA 9.68B RUPEES VS 6.04B (YOY); Q2 EBITDA MARGIN 64.44% (YOY)

GROWW: Q2 REVENUE 15B RUPEES VS 10.2B (YOY)

Trump says amnesty for illegal immigrants will "never happen"

DIESEL SUPPLIES TO REMAIN CONSTRAINED WELL INTO 2027, IEA WARNS

IEA: SEES 2027 WORLD OIL SUPPLY 3.94M BPD ABOVE DEMAND (PREV FORECAST 3.73M BPD ABOVE); RESTRICTED MIDDLE DISTILLATE SUPPLY TO PERSIST WELL INTO 2027 AS DIESEL MARKETS UNDER SIGNIFICANT STRAIN FROM PROLONGED DISRUPTIONS

ELECON ENGINEERING — Q2 RESULTS

Net Profit: ₹96.35 Cr ↑10% YoY | ↑37% QoQ

Revenue: ₹638.94 Cr ↑11% YoY | ↑23% QoQ

EBITDA: ₹147.90 Cr ↑18% YoY | ↑38% QoQ

EBITDA Margin: 23.1% vs 21.7% YoY | 20.6% QoQ

BHEL — Q2 FY27 RESULTS

Net Profit: ₹809.62 Cr ↑120% YoY | ↑112% QoQ

Revenue: ₹9,300.35 Cr ↑24% YoY | ↑21% QoQ

EBITDA: ₹1,025.80 Cr ↑77% YoY | ↑104% QoQ

EBITDA Margin: 11.0% vs 7.7% YoY | 6.5% QoQ

BHEL — Q2 FY27 RESULTS VS ESTIMATES

Net Profit: ₹810 Cr vs ₹654.4 Cr estimated — Beat by 23.8%

Revenue: ₹9,300 Cr vs ₹9,236 Cr estimated — Beat by 0.7%

EBITDA Margin: 1% vs 0.5% estimated — Beat by 50 bps

Apollo Hospital, Max Healthcare and Hospital In Focus – Big Negative; Big Margin Cut Could Come

Central Government Affidavit Says
Average markup on non-scheduled cancer drugs stands at 170%

Some anti-cancer drugs have markups of 700% or more

Allegations of drug retail margins exceeding 1,800% were put to committee

Govt says anti-cancer drug market is worth about 12,500 cr/year

Market for non-scheduled cancer drugs with no price cap is 10,000 cr/year

Consumable margins of 100% to more than 1,000% are prevalent in hospitals

Healthcare consumers have limited ability to compare prices before treatment

Patients often cannot substitute medicines prescribed during hospital treatment

Cancer patients operate with little bargaining power in treatment decisions

NPPA duty extends beyond monitoring prices to preventing profiteering

Canara Bank - TV interview- Guidance up

- See Credit growth in H2 better than earlier guidance

- Expects improvement in net interest margins ahead

BEML: ABAKKUS FLEXI CAP FUND (SUNIL SINGHANIA) NAME APPEARS WITH 1.08% STAKE IN CO DURING Q2

THELEELA: Q2 CONS NET PROFIT 946M RUPEES VS 747M (YOY); EST 792M

THELEELA: Q2 EBITDA 2B RUPEES VS 1.6B (YOY); Q2 EBITDA MARGIN 47.05% VS 51.74% (YOY)

THELEELA: Q2 REVENUE 4.12B RUPEES VS 3.1B (YOY)

BlackRock Q3 26 Earnings:

- AUM: $15.49T (est $15.57T)

- Adjusted EPS: $15.93 (est $14.1)

- Net Income: $1,659M

- Revenue: $7,752M (est $7,520M)

- Demand For Capital Is Growing Across Global Economy

- Raised $68B In Private Markets Over Last Twelve Months

- AI Infrastructure Partnership Made First Deployment This Quarter

HDBFS: Q2 SL NET PROFIT 7.8B RUPEES VS 5.81B (YOY); EST 8.13B

HDBFS: Q2 GNPA 2.43% VS 2.34% (QOQ); Q2 NNPA 1.09% VS 1.04% (QOQ)

HDBFS: Q2 REVENUE 50B RUPEES VS 45.45B (YOY)

EU SET TO LIFT SANCTION ON CHINESE FIRM TO SAVE ASML SUPPLIER

TATA TECHNOLOGIES — Q2 FY27 RESULTS

Net Profit: ₹171 Cr ↑4% YoY | ↓5% QoQ

Revenue: ₹1,699 Cr ↑28% YoY | ↑2% QoQ

EBITDA: ₹273 Cr ↑32% YoY | ↑2% QoQ

EBITDA Margin: 16.1% vs 15.7% YoY | 16.1% QoQ

BofA Q3 26 Earnings:

- FICC Trading Revenue Ex-DVA: $2.55B (est $2.86B)

- Equities Trading Revenue Ex-DVA: $2.51B (est $2.63B)

- Total Corporation Investment Banking Fees (Excl. Self-Led): $1.8B

- Results Include Regulatory Settlement Charge Of $1.2B, Or $0.17 Per Share

- Asset Quality Continued To Improve; Liquidity And Capital Remained Strong

- Healthy Activity From Consumer, Wealth Management, Business And Commercial Clients

- Investment Banking And Sales And Trading Revenues Lower; Commercial Lending Grew In Every Client Segment

US inflation rises to 3.7%, higher than expectations.